Skip to main content

Table 2 Comparison of chromosomal abnormalities * seen in patients with and without CNS involvement

From: Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults

Variables Total (n = 378) Patients with CNS involvement (n = 19) Patients without CNS involvement (n = 359) Pvalue
Number (%) of patients
Karyotype     0.378
Favorable 50 3(15.8) 47(13.1)  
Intermediate 264 15(78.9) 249(69.4)  
Unfavorable 64 1(5.3) 63(17.5)  
t(8;21) 34 1(5.3) 33(9.2) >0.999
inv(16) 16 2(10.5) 14(3.9) 0.189
11q23 abnormalities 14 4(21.1) 10(2.8) 0.003
-5/5q- 1 0(0) 1(0.3) >0.999
-7/7q- 6 0(0) 6(1.7) >0.999
t(7;11) 4 0(0) 4(1.1) >0.999
t(6;9) 2 0(0) 2(0.6) >0.999
+8 17 1(5.3) 16(4.5) 0.592
  1. *Three hundred and seventy-eight patients had cytogenetic profiles at diagnosis. The remaining 17 patients did not have data of cytogenetic profiles because of inadequate metaphase cells for alalysis.
  2. Favorable, t(8;21), inv (16); unfavorable, -7, del(7q), -5, del(5q), 3q abnormality, complex abnormalities; Intermediate, normal karyotype and other abnormalities.
  3. Includes only simple chromosomal abnormalities with 2 or fewer changes, but not those with complex abnormalities with 3 or more aberrations.
  4. Abbreviation: CNS central nervous system.